LZLiubov M. Zakhartseva

Liubov M. Zakhartseva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liubov M. Zakhartseva has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Differential diagnosis of primary and metastatic ovarian carcinomas

    by L. M. Zakhartseva, O. P. Manzhura, I. Yu. Vashchenko, Ye. V. Maistrenko, O. M. Kravchuk, K. M. Shatrova, O. H. Rudnytska

    Ovarian tumors constitute 3.4 % of the structure of oncological diseases in women worldwide. However, the ovaries are also a common target for metastasis of carcinoma from other organs. Conducting differential diagnosis between primary carcinoma and metastasis is often challenging. The aim of this study is to highlight the issues of morphological and immunohistochemical differential diagnosis of primary ovarian carcinomas and metastases from carcinomas of various organs to the ovaries. Materials and methods. Data analysis of clinical and pathohistological studies of 381 patients. Paraffin sections for pathohistological studies were stained with hematoxylin and eosin using standard methodology. Immunohistochemical studies were conducted in 161 cases using a panel of antibodies: cytokeratins, estrogen receptors, progesterone receptors, CA125, TTF1, Vimentin, CDX2, Villin, Chromogranin A, Synaptophysin, CD56, GATA, p53, Inhibin A, FOXL-2, PAX-8, Ki-67. The specimens were examined and analyzed using the Axioskop 40 microscope (Zeiss) with the AxioCam MRc camera (Zeiss). Results. The article discusses key issues of differential diagnosis of primary and metastatic ovarian carcinomas based on a large clinical and operational material. The application of an adequate panel of immunohistochemical antibodies for verification is considered. The results of the frequency of occurrence of different histological variants of ovarian carcinomas and metastases to the ovaries from carcinomas of other organs are provided based on our own research from 2019 to 2023. The main morphological and immunohistochemical indicators for practical use in the work of a pathologist in the verification of ovarian tumors are presented. An example of forming an antibody panel, taking into account clinical and morphological indicators in a specific clinical case from our own practice, is given. Conclusions. Metastases of carcinomas from other organs to the ovaries constitute half of all cases requiring immunohistochemical investigation based on morphological structure. The most common are metastases from breast and colorectal cancers. However, the diagnosis of metastatic intestinal carcinoma is particularly challenging, as there is usually no clear clinical picture. In the differential diagnosis of primary and metastatic ovarian tumors, a comprehensive approach to analyzing the clinical presentation, microscopic structure of the tumor, and the surrounding tissue plays a significant role. Additionally, the formation of an antibody panel, taking into account these data, is crucial. The article provides a list of antibodies that have demonstrated greater effectiveness in our work.

  • Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: risk factor or clinical marker of breast cancer

    by Olga Lobanova, Nataliia Medvedieva, Liliia Fishchuk, Olha Dubitska, Valeriy Cheshuk, Roman Vereshchako, Liubov Zakhartseva, Zoia Rossokha, Natalia Gorovenko

    Background In this study, we compared the contribution of pathogenic variants of the BRCA1/2 genes (5382insC, 185delAG, 6174delT, 4153delA, T300G) and hypermethylation of the BRCA1 gene promoter region to the risk of breast cancer and clinical features in women. Methods This study enrolled 74 women (tumor tissue, blood) with newly diagnosed breast cancer and 62 women (blood) without oncological pathology (control group). Molecular genetic testing of samples and determination of hypermethylation status were performed on freshly collected material with the addition of a preservative before the procedure of DNA isolation. Results Hypermethylation of the BRCA1 gene promoter in women is a risk breast cancer factor (χ2 = 19.10, p = 0.001, OR = 16.25 (3.67–71.92)) and is more common than major pathogenic variants in the BRCA1/2 genes. The patients with the BRCA1 gene promoter hypermethylation were more likely to be diagnosed with late-stage metastatic cancer (χ2 = 4.31, p = 0.038, OR = 4.04 (1.19–13.65)). Hypermethylation of the BRCA1 gene promoter was predominant in tumor tissue among BC patients without family history compared to patients with cancer in relatives. Conclusion We proved that hypermethylation of the BRCA1 gene promoter is a risk factor for breast cancer and possibly an early biological marker of clinical onset, as its presence contributed to rapid disease progression with metastasis. The high frequency of hypermethylation in the examined breast cancer patients may be a consequence of environmental factors pressure on the risk of the disease development. Further large-scale studies are needed for the clinical application of the results.


  • Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine

    by Anastasiia Samusieva, Svitlana Serga, Sergiy Klymenko, Lyudmila Rybchenko, Bohdana Klimuk, Liubov Zakhartseva, Natalia Gorovenko, Olga Lobanova, Zoia Rossokha, Liliia Fishchuk, et al.

    Purpose The gene BRCA1 plays a key role in DNA repair in breast and ovarian cell lines and this is considered one of target tumor suppressor genes in same line of cancers. The 5382insC mutation is among the most frequently detected in patients (Eastern Europe) with triple-negative breast cancer (TNBC). In Ukraine, there is not enough awareness of necessity to test patients with TNBC for BRCA1 mutations. That is why this group of patients is not well-studied, even through is known the mutation may affect the course of disease. Methods The biological samples of 408 female patients were analyzed of the 5382insC mutation in BRCA1. We compared the frequency of the 5382insC mutation in BRCA1 gene observed in Ukraine with known frequencies in other countries. Results For patients with TNBC, BRCA1 mutations frequency was 11.3%, while in patients with luminal types of breast cancers, the frequency was 2.8%. Prevalence of 5382insC among TNBC patients reported in this study was not different from those in Tunisia, Poland, Russia, and Bulgaria, but was higher than in Australia and Germany. Conclusion The BRCA1 c.5382 mutation rate was recorded for the first time for TNBC patients in a Ukrainian population. The results presented in this study underscore the importance of this genetic testing of mutations in patients with TNBC. Our study supports BRCA1/2 genetic testing for all women diagnosed with TNBC, regardless of the age of onset or family history of cancer and not only for women diagnosed with TNBC at <60y.o., as guidelines recommend.


  • Open Access

    Predictive value of morphological features and proliferative markers (mitotic index, Ki-67, PHH3) in bronchopulmonary neuroendocrine tumors

    by L. M. Zakhartseva, H. Ye. Chytaieva

    Мета роботи – оцінювання зв’язку мітотичного індексу (MI), некрозу, імуногістохімічних (ІГХ) маркерів проліферації Ki-67, PHH3 та їхньої цінності як предикторів агресивності нейроендокринних пухлин (НЕП) легень. Матеріали та методи. Дослідження здійснили, використавши операційний і біопсійний матеріал, що отримали від 64 пацієнтів із НЕП легень до призначення їм хімієтерапії. Виконали морфологічне та ІГХ дослідження. MI, вираженість некрозу, експресію Ki-67 і PHH3, метастатичні ураження та виживаність хворих оцінювали за допомогою методів непараметричної статистики. Результати. Виявили статистично вірогідний зв’язок між вираженістю некрозу та виживаністю пацієнтів (р = 0,021). Це стосувалося порівняння груп хворих без вогнищ некрозу у тканині пухлини та з екстенсивними вогнищами некрозу (p = 0,023). MI достовірно пов’язаний із наявністю метастазів у лімфатичних вузлах (p = 0,003) і віддалених метастазів (p = 0,029). Визначили значущий прямий зв’язок між рівнем Ki-67 і MI (р < 0,001), MI та експресією PHH3 (p < 0,001). Але не виявили вірогідний зв’язок між рівнями Ki-67 і PHH3 (p = 0,240), як і між Ki-67, наявністю вогнищ некрозу та метастазів. Рівень Ki-67 також не впливав на виживаність пацієнтів. Експресія PHH3 та результати її оцінювання виявилися доволі неоднозначними. Рівень експресії PHH3 нижчий, ніж очікуваний, не перевищував такий для Ki-67 і MI. Висновки. MI та некроз – надійні маркери оцінювання агресивності НЕП легень. MI статистично вірогідно пов’язаний із наявністю метастатичного ураження, а екстенсивний некроз – із показниками виживаності. Ki-67 вірогідно пов’язаний із MI. Не виявили вірогідний зв’язок між експресією Ki-67 і PHH3, а також рівнем Ki-67 і морфологічними особливостями пухлини, прогресією захворювання та прогнозом. Усупереч нашим припущенням, PHH3 при НЕП легень не є діагностичним або прогностичним чинником.

  • Open Access

    INFLUENCE OF CHRONIC NON-GASEOUS ACIDOSIS ON BONE TISSUE

    by Yu. V. Perepelytsia, L. M. Zakhartseva, V. A. Mikhnev, Ia. A. Ushko

    The urgency of the problem is due to the high prevalence among the population in all countries of the world and socio-economic losses associated with serious complications of osteoporosis. Chronic non-gaseous acidosis leads to disruption of many metabolic processes, which causes dysfunction of some organs, namely, can lead to decreased kidney function, exacerbate cardiovascular disease, the development of osteoporosis. Different types of non-gaseous acidosis are accompanied by changes in protein metabolism, which lead to the development of osteoporosis. Aim: to study the structural features of the bone tissue of the femur in chronic non-gaseous acidosis. Methods. The experiments were carried out on 60 intact white outbred male rats weighing 120-180 g, which were kept on a balanced diet of vivarium. Chronic non-gaseous acidosis was simulated by daily intragastric administration with a probe for 60 days 20 mmol/kg NH4CL. The control animals were injected with the same amount of tap water. Histological examination and osteometry were used to study the structure, length and thickness of the rat femur. Free, bound, and total oxyproline in rat urine was determined by biochemical method. Results. In chronic non-gaseous acidosis after 6 months there is a tendency to reduce the length and thickness of the femur, but does not differ significantly from the control group. In the urine of rats of the experimental group, the total oxyproline increases mainly due to an increase in free oxyproline, which indicates the predominance of collagen degradation over repair. The histological structure of the bone is disturbed due to the thinning of the bone beams, the intercellular matrix is disorganized, in some places there is its "defibering" with the formation of foci of destruction and cylindrical "lumens". There is a violation of the crystalline structure of bone tissue, its uneven calcification, the formation of cracks in the bone beams. Studied literature sources and our research indicate that chronic non-gaseous acidosis has a pathogenic effect on the histological structure of bone. Acidosis is a stress factor that increases the level of glucocorticoids. Glucocorticoids inhibit type I collagen synthesis and increase the expression of collagenase 3, which promotes collagen degradation. Collagen is a source of amino acids that are the substrate for renal ammoniogenesis. Renal ammoniogenesis is a compensatory mechanism in chronic non-gaseous acidosis, which required for restores the normal ratio between fixed cations and anions blood plasma. Thus, the violation of the organic basis of bones is the body's adaptation to chronic non-gaseous acidosis. Conclusions. Chronic non-gaseous acidosis simultaneously leads to thinning and disorganization of the intercellular matrix, disruption of the crystal structure of bone tissue, which indicates its important role in the development of osteoporosis. In chronic non-gaseous acidosis, the concentration of oxyproline in the urine increases, which is a marker of the destruction of collagen in the organic matrix of bone.

  • Open Access

    Tumor-infiltrating lymphocytes in triple negative breast cancer

    by L. M. Zakhartseva, M. O. Yanovytska

    Пухлиноінфільтруючі лімфоцити при тричі негативних карциномах молочної залози


  • Open Access

    ASSOCIATION OF GENOTYPES OF POLYMORPHISMS OF GENES FGFR2, LSP, AND LOC643714 WITH THE RISK OF A POSITIVE MUTATIONAL STATUS OF THE HER-2/NEU GENE IN BREAST CANCER PATIENTS

    by Bogdana Klimuk, Svitlana Polinik, Lyudmila Ribchenko, Lubov Zakhartseva, Oleksyi Dugan, Sergiy Klymenko

    Breast cancer is the result of genetic and environmental factors that lead to the accumulation of mutations in key regulatory genes. Genetic predisposition to cancer pathologies may be due to mutations in individual genes, such as in BRCA1 and BRCA2, or may be due to a cumulative effect as a result of the interaction of genes of low penetrance. This paper reviews the alleles that determine the risk of high and low penetrance breast cancer and discusses ongoing efforts to identify additional susceptibility genes. The identification of propensity genes is a prerequisite for an individualized assessment of breast cancer risk and a decrease in the incidence of breast cancer. The main goal of this study is to determine the associations of polymorphic variants rs2981582 and rs1219648 of FGFR2, rs3817198 of LSP and rs3803662 of LOC643714 with the risk of breast cancer and the development of a positive mutational status of Her-2/neu. The study group included 300 women diagnosed with breast cancer. Fluorescent in situ hybridization was performed on tumor tissue materials from these patients to determine the amplification status of the Her-2/neu. The distribution of genotypes and alleles was performed by real-time polymerase chain reaction for the following polymorphic variants rs1219648 of FGFR2 (n = 44), rs2981582 of FGFR (n = 99), rs3817198 of LSP1 (n = 75) and rs3803662 of the LOC643714 (n = 82). Among the studied genotypes of polymorphic variants rs3817198 of LSP1, rs3803662 of LOC643714, rs2981582 and rs1219648 of FGFR2, with the inclusion of the risk allele, the association of the propensity to develop breast cancer in women according to the multiplicative model of inheritance (p> 0.05) was not determined. According to the codominant inheritance model, there is an associative relationship with the risk of breast cancer and polymorphism rs3817198 of LSP1, rs3803662 of LOC64371 and rs2981582 of FGFR2 with homozygous genotypes for rare alleles (p <0.05). Women with a positive amplification status of the Her-2/neu, patients with breast cancer, were more likely to carry the risk allele G (OR = 4.80; 95% CI 1.21–28.04, p <0.05) and genotype GG ( OR = 5.82; 95% CI 1.38-16.74, p <0.05) rs3803662 polymorphism of LOC643714, compared with a group of women with negative amplification status of Her-2/neu in patients diagnosed with breast cancer. The results of this study can be useful for searching for additional genetic predictors of breast cancer and a positive mutational status of Her-2/neu.

  • Open Access

    HISTOLOGICAL FEATURES OF CHROMOPHOBE RENAL CELL CARCINOMA

    by V. V. Baranovska, A. M. Romanenko, L. M. Zakhartseva

    Introduction. Renal neoplasms are a common disease. Differential diagnostics of different tumor subtypes for prognosis and treatment is necessary given that some of them, like renal cell oncocytomas, are benign, and others, like chromophobe renal cell carcinomas, are malignant. Unfortunately, the histological similarity between these tumors makes accurate diagnostics difficult. In some cases, additional diagnostic methods such as immunohistochemistry should be used. The aim of our study is to analyze the histological characteristics of chromophobe renal cell carcinomas and renal oncocytomas, in order to specify their pathognomonic features, allowing for the confirmation of the diagnosis. Materials and methods. We used data from histories of disease and histological postoperative material of 198 patients with chromophobe renal cell carcinoma and renal oncocytoma. After the diagnosis was confirmed, we described the histological features of the tumors and calculated their relative prevalence amongst the renal oncocytoma and chromophobe renal cell carcinoma tissues. To conclude, we identified the histological features that are more likely to be present in the case of chromophobe renal cell carcinoma. Conclusions. Chromophobe renal cell carcinomas are present in 31 % of our samples. Tumors are more prevalent in patients in their sixth and seventh decade. Most chromophobe renal cell carcinomas are unilateral. Chromophobe renal cell carcinomas have a polymorphic histological structure. The classic variant of chromophobe renal cell carcinoma is more common than the eosinophilic one. A mixed variant of chromophobe renal cell carcinoma is present in a minority of cases. The most common features of ChRCC are solid and alveolar growth patterns, clear and reticular cytoplasm, raisinoid nuclei. After comparing the relative prevalence of various histological features in renal oncocytomas to those present in chromophobe renal cell carcinomas, we are able to ascertain that chromophobe renal cell carcinomas tend to exhibit the following features significantly more often than renal oncocytomas: differing nuclear size, raisinoid nuclei, reticular cytoplasm, clear cytoplasm. The particular features mentioned in the preceding paragraph, can be present on a small subset of the tumor tissue, and are thus, often missed during analysis, which can lead to misdiagnosis. In order to mitigate this risk, we recommend analyzing a big sample of tumor tissue and using additive methods such as immunohistochemistry with biomarkers CD 10 (56C6), CD 68 (KP1), Cytokeratin 7 (OV-TL 12/30), CD117/c-kit, Vimentin (Vim3B4), S-100 (4C4.9). Вступ і мета. Пухлини нирок є розповсюдженим станом, при якому диференційна діагностика гістологічних варіантів є принциповою для визначення прогнозу та лікування. В той самий час, це може викликати складності через гістологічну подібність різних видів новоутворень. Для вирішення цього питання необхідним є використання додаткових методів на зразок імуногістохімічної діагностики. Метою нашого дослідження є вивчення різноманіття будови хромофобної карциноми та виявлення патогномонічних гістологічних рис для її верифікації. Матеріали та методи. Досліджено історії хвороби та гістологічні препарати оперативно видалених пухлин нирки 198 пацієнтів із діагнозом онкоцитоми нирки або хромофобної карциноми нирки. Після підтвердження діагнозу визначено наявність різних гістологічних характеристик хромофобної карциноми нирки і розраховано вірогідність їх переважання в порівнянні з онкоцитомою нирки. З огляду на це, визначено ті гістологічні характеристики хромофобної карциноми нирки, вірогідність прояву яких була найвищою. Висновки. Хромофобна карцинома нирки зустрічається в третині досліджуваних пухлин нирки, здебільшого серед пацієнтів на шостій та сьомій декаді життя. Частіше пухлина одностороння та безсимптомна. Хромофобна карцинома нирки має різноманітну гістологічну будову, що ускладнює її діагностику. Класичний варіант хромофобної карциноми нирки спостерігається частіше за еозинофільний. Складним для діагностики хромофобної карциноми нирки є змішаний варіант, який має структури, схожі на інші види нирковоклітинних пухлин. Найбільш частими гістологічними рисами хромофобної карциноми нирки були солідний чи альвеолярний патерни росту, світла цитоплазма з ретикулярною структурою та родзиноподібне ядро. При порівнянні розповсюдженості різних гістологічних рис при хромофобній...

  • A genomic copy number signature predicts radiation exposure in post‐Chernobyl breast cancer

    by Christina M. Wilke, Herbert Braselmann, Julia Hess, Sergiy V. Klymenko, Vadim V. Chumak, Liubov M. Zakhartseva, Elena V. Bakhanova, Axel K. Walch, Martin Selmansberger, Daniel Samaga, et al.

    Breast cancer is the second leading cause of cancer death among women worldwide and besides life style, age and genetic risk factors, exposure to ionizing radiation is known to increase the risk for breast cancer. Further, DNA copy number alterations (CNAs), which can result from radiation‐induced double‐strand breaks, are frequently occurring in breast cancer cells. We set out to identify a signature of CNAs discriminating breast cancers from radiation‐exposed and non‐exposed female patients. We analyzed resected breast cancer tissues from 68 exposed female Chernobyl clean‐up workers and evacuees and 68 matched non‐exposed control patients for CNAs by array comparative genomic hybridization analysis (aCGH). Using a stepwise forward–backward selection approach a non‐complex CNA signature, that is, less than ten features, was identified in the training data set, which could be subsequently validated in the validation data set (p value < 0.05). The signature consisted of nine copy number regions located on chromosomal bands 7q11.22‐11.23, 7q21.3, 16q24.3, 17q21.31, 20p11.23‐11.21, 1p21.1, 2q35, 2q35, 6p22.2. The signature was independent of any clinical characteristics of the patients. In all, we identified a CNA signature that has the potential to allow identification of radiation‐associated breast cancer at the individual level.


  • Expression of miRNA‐26b‐5p and its target TRPS1 is associated with radiation exposure in post‐Chernobyl breast cancer

    by Christina M. Wilke, Julia Hess, Sergiy V. Klymenko, Vadim V. Chumak, Liubov M. Zakhartseva, Elena V. Bakhanova, Annette Feuchtinger, Axel K. Walch, Martin Selmansberger, Herbert Braselmann, et al.

    Ionizing radiation is a well‐recognized risk factor for the development of breast cancer. However, it is unknown whether radiation‐specific molecular oncogenic mechanisms exist. We investigated post‐Chernobyl breast cancers from radiation‐exposed female clean‐up workers and nonexposed controls for molecular changes. Radiation‐associated alterations identified in the discovery cohort (n = 38) were subsequently validated in a second cohort (n = 39). Increased expression of hsa‐miR‐26b‐5p was associated with radiation exposure in both of the cohorts. Moreover, downregulation of the TRPS1 protein, which is a transcriptional target of hsa‐miR‐26b‐5p, was associated with radiation exposure. As TRPS1 overexpression is common in sporadic breast cancer, its observed downregulation in radiation‐associated breast cancer warrants clarification of the specific functional role of TRPS1 in the radiation context. For this purpose, the impact of TRPS1 on the transcriptome was characterized in two radiation‐transformed breast cell culture models after siRNA‐knockdown. Deregulated genes upon TRPS1 knockdown were associated with DNA‐repair, cell cycle, mitosis, cell migration, angiogenesis and EMT pathways. Furthermore, we identified the interaction partners of TRPS1 from the transcriptomic correlation networks derived from gene expression data on radiation‐transformed breast cell culture models and sporadic breast cancer tissues provided by the TCGA database. The genes correlating with TRPS1 in the radiation‐transformed breast cell lines were primarily linked to DNA damage response and chromosome segregation, while the transcriptional interaction partners in the sporadic breast cancers were mostly associated with apoptosis. Thus, upregulation of hsa‐miR‐26b‐5p and downregulation of TRPS1 in radiation‐associated breast cancer tissue samples suggests these molecules representing radiation markers in breast cancer.